ABOUT / THE PUBLISHER
About GHK-Cu Meds: What This Site Is, Plainly
An independent editorial project that boxes and cites the published copper-peptide record. Nothing here is sold; nothing here is prescribed.
What GHK-Cu Meds is
GHK-Cu Meds is an independent editorial project that publishes summaries of the peer-reviewed research literature on GHK-Cu, the copper tripeptide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The approach is plain and consistent: lead with what a study measured, attribute it to its source, and name the limits. Each page boxes its key numbers and links every quantitative claim to a citation on the references page. Where the evidence is in vitro or rodent, we say so; where there is no validated human pharmacokinetic data, we say that too.
What "Meds" means here
The word "Meds" in this site's name is editorial framing, not a service claim. It signals the register — a no-nonsense, plain-spoken reading of the research — not a pharmacy, a prescriber, or a treatment provider. GHK-Cu Meds does not offer treatment, consultation, or prescription services of any kind, and nothing on this site should be read as a recommendation to use GHK-Cu by any route.
GHK-Cu has no FDA- or EMA-approved therapeutic indication by any route [3]. Topical Copper Tripeptide-1 is a legally marketed cosmetic ingredient with a long safety record; injectable and other systemic use is unapproved and research-only [3]. We document the science. The decisions that follow from it belong to readers and, where relevant, their qualified professionals.
How the digest is built
Every page is assembled from the published record: PubMed-indexed primary studies, PMC-hosted reviews, and registered trials. The citation list is the spine of the site, and we update it as new formulation and delivery research appears — the 2023 liposome and hyaluronic-acid synergy studies [7][8], the 2024 ionic-liquid microemulsion hair study [14] and the 2025 anti-wrinkle review [11] are the most recent additions.
We carry conservative figures by default. When the literature itself flags an over-cited number — as it does with the '4,000 genes' claim versus the verified roughly 2,100-gene threshold [4] — we report the verified figure and note the discrepancy rather than the louder one.
What we will not do
We do not state a human dose. GHK-Cu has no approved systemic indication [3], so every dose on this site is described as it was administered in a study — which species, which route, which concentration — and never as a recommendation. We do not name brand-name products, we do not link to vendors, and we do not present community injection protocols, because none of them rests on published human pharmacokinetic data [3].
We also flag the structural limits of the field rather than paper over them: much of the foundational mechanistic and review literature originates with a single investigator and close colleagues, so independent replication of the broader gene-expression and anti-aging claims is limited [4]. Naming that is part of reporting the science honestly. The aim of GHK-Cu Meds is a record a reader can trust precisely because the gaps are marked as clearly as the findings.